Details of the Drug Combinations

General Information of This Drug (ID: DMF9M57)

• Drug Name: Cotellic (DMF9M57)
• Synonyms: Cobimetinib fumarate; Cobimetinib Fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate

Indication

Melanoma; ICD 11: 2C30; Status: Phase 3 [1]; Breast cancer; ICD 11: 2C60-2C65; Status: Phase 2 [2]; Head and neck cancer; ICD 11: 2D42; Status: Phase 1 [2]; Renal cell carcinoma; ICD 11: 2C90; Status: Phase 1 [2]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 1 [3]; Urothelial carcinoma; ICD 11: 2C92.0; Status: Phase 1 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

36 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AZD8055 + Cotellic	DCQFZ45	AZD8055	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
AZD8055 + Cotellic	DCDY037	AZD8055	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
AZD8055 + Cotellic	DCHQM09	AZD8055	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Buparlisib + Cotellic	DCJ2V56	Buparlisib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
Buparlisib + Cotellic	DCRD7BW	Buparlisib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
Buparlisib + Cotellic	DC1URIC	Buparlisib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
Cotellic + Panobinostat	DC9U1FX	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Everolimus + Cotellic	DCLBUJD	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Everolimus + Cotellic	DC436QT	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
Everolimus + Cotellic	DC14076	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
GDC-0068 + Cotellic	DCUJIAF	GDC-0068	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
GDC-0068 + Cotellic	DCVNHGU	GDC-0068	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
GDC-0068 + Cotellic	DC7FFBO	GDC-0068	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
GDC-0084 + Cotellic	DC60IMQ	GDC-0084	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
GDC-0084 + Cotellic	DCSD7MA	GDC-0084	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
GDC-0084 + Cotellic	DCP8Q4J	GDC-0084	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
GDC-0980/RG7422 + Cotellic	DCTJOWS	GDC-0980/RG7422	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
GDC-0980/RG7422 + Cotellic	DCHLHA7	GDC-0980/RG7422	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
GDC-0980/RG7422 + Cotellic	DCBEPIW	GDC-0980/RG7422	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
GSK690693 + Cotellic	DC7VE8K	GSK690693	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
GSK690693 + Cotellic	DCRSWNG	GSK690693	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
GSK690693 + Cotellic	DCO6RGX	GSK690693	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
MK-2206 + Cotellic	DCLUT9S	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
MK-2206 + Cotellic	DCM9SVR	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
PF-04691502 + Cotellic	DC8GKV1	PF-04691502	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
PF-04691502 + Cotellic	DCUU94U	PF-04691502	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
PF-04691502 + Cotellic	DC7OIAL	PF-04691502	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
RTB101 + Cotellic	DCXJOW8	RTB101	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
RTB101 + Cotellic	DCIK6JV	RTB101	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
RTB101 + Cotellic	DC9B0VR	RTB101	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
Sapanisertib + Cotellic	DCPYCZJ	Sapanisertib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
Sapanisertib + Cotellic	DCPC72V	Sapanisertib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
Sapanisertib + Cotellic	DCML66X	Sapanisertib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
Triciribine + Cotellic	DC3DVEO	Triciribine	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Triciribine + Cotellic	DCPHXGK	Triciribine	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
Triciribine + Cotellic	DCIF4IT	Triciribine	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cotellic + GDC-0068	DC5EVDK	GDC-0068	Neoplasms	[6]
Cotellic + MK-4827	DCLCOR5	MK-4827	OVARIAN CANCER	[7]
Cotellic + Alectinib	DCYKZTZ	Alectinib	Non-small Cell Lung Cancer	[8]
GDC0941 + Cotellic	DC1SD8X	GDC0941	Solid Tumors	[9]
Vemurafenib + Cotellic	DCD7H3V	Vemurafenib	Malignant Melanoma	[10]
Venetoclax + Cotellic	DC1T534	Venetoclax	Leukemia, Myeloid, Acute	[11]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01106599) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [6] ClinicalTrials.gov (NCT01562275) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
• [7] ClinicalTrials.gov (NCT03695380) A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
• [8] ClinicalTrials.gov (NCT03202940) A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
• [9] ClinicalTrials.gov (NCT00996892) Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
• [10] ClinicalTrials.gov (NCT01271803) A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
• [11] ClinicalTrials.gov (NCT02670044) A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy